Differential Hemodynamic Effects of the Nitric Oxide Donor Pirsidomine in Comparison to SIN-1, Nitroprusside and Nitroglycerin

Pharmacology

Volumn 52, Issue 2, 1996, Pages 92-100

  Arkonac, Burak M ^a   Kersten, Judy R ^a   Wynsen, John C ^a   Nijhawan, Niraj ^a   Warltier, David C ^a  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Conscious dogs; Nitric oxide donor; Nitroglycerin; Nitroprusside; Pirsidomine; SIN 1

Indexed keywords

GLYCERYL TRINITRATE; LINSIDOMINE; NITROPRUSSIDE SODIUM; PIRSIDOMINE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL EXPERIMENT; AORTA PRESSURE; ARTICLE; BLOOD FLOW VELOCITY; CORONARY ARTERY BLOOD FLOW; CORONARY HEMODYNAMICS; CORONARY VASCULAR RESISTANCE; DOG; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART OUTPUT; HEART STROKE VOLUME; HEMODYNAMICS; INOTROPISM; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC VASCULAR RESISTANCE;

EID: 0030066413     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139372     Document Type: Article

References (21)

1. Bates JN. Baker MT, Guerra R Jr, Harrison DG: Nitric oxide generation from nitroprusside by vascular tissue: Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem Pharmacol 1991;42(suppl): 157-165.
2. Chung SJ. Fung HL: Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J Pharmacol ExpTher 1990:253:614-619.
3. Bohn H. Schonafmger K: Oxygen and oxidation promote the release of nitric oxide from sydnonimines. J Cardiovasc Pharmacol 1989:14 (suppl):6-12.
4. Fcelisch M. Ostrowski J. Noack E: On the mechanism of NO release from sydnonimines. J Cardiovasc Pharmacol 1989; 14(suppl): 13-22.
5. Mulsch A, Hecker M, Mordvintcev PI. Vanin AF, Busse R: Enzymic and nonenzymic release of NO accounts for the vasodilator activity of the metabolites of CAS 936, a novel long-acting svdnonimine derivative. Naunyn Schmiedebergs Arch Pharmacol 1993;347:92-100.
6. Kerstcn JR. Brayer AP, Pagel PS, Tcssmer JP. Warltier DC: Perfusion of ischemic myocardium during anesthesia with scvoflurane. Anesthesiology 1994:81:995-1004.
7. Theroux P, Franklin D, Ross J Jr, Kemper WS: Regional myocardial function during acute coronary artery occlusion and its modification by pharmacologic agents in the dog. CircRes 1974:35:896-908.
8. Rooke GA. Fcigl EO: Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. CircRes 1982;50:273-286.
9. Bohn H, Beyerle R. Martorana PA, Schonafmger K: CAS 936. a novel svdnonimine with direct vasodilating and nitric oxide-donatir.g properties: Effects on isolated blood vessels. J Cardiovasc Pharmacol 1991; 18:522-527.
10. La Rochelle CD, Dubois-Rande JL, Richard V. Hittinger L, Giudicelli J-F. Bordeaux A: The role of NO release in the control of large and small coronary artery tone in conscious dogs. J Cardiovasc Pharmacol 1993;22(suppl): 17-21.
11. Wang J, Zhao G. Shen W, Ochoa M. Moore D. Hubbard JW. Hintze TH: Effects of an orally active NO-releas-ing agent, CAS 936, and its active metabolite, 3754. on cardiac and coronary dynamics in normal conscious dogs and after pacing-induced heart failure. J Cardiovasc Pharmacol 1993;22(suppl):5l-58.
12. Bohn H. Martorana PA. Schonafin-gcr K: Cardiovascular effects of the new nitric oxide donor, pirsido-mine. Hemodynamic profile and tolerance studies in anesthetized and conscious dogs. Eur J Pharmacol 1992;220:71-78.
13. Martorana PA. Kettenbach B, Bohn H, Schonafmger K. Henning R: An-tiischemic effects of pirsidomine, a new nitric oxide donor. Eur J Pharmacol 1994;257:267-273.
14. Wainwright CL, Martorana PA: Pirsidomine, a novel nitric oxide donor, suppresses ischemic arrhythmias in anesthetized pigs. J Cardiovasc Pharmacol 1993;22(suppl): 44-50.
15. Shah AM, Spurgeon HA. Sollott SJ. Talo A. Lakatta EG: 8-bromo-cGMP reduces the myofilament response to C’a-* in intact cardiac myocytes. Circ Res 1994:74:970-978. '
16. Grocott-Mason R. Fort S, Lewis MJ. Shah AM: Myocardial relaxant effect of exogneous nitric oxide in isolated ejecting hearts. Am J Physiol 1994:266: H1699-H1705.
17. Kurz MA, Lamping KG, Bates JN. Eastham CL, Marcus ML. Harrison DG: Mechanisms responsible for the heterogeneous coronary micro-vascular response to nitroglycerin. CircRes 1991;68:847-855.
18. Harrison DG, Bates JN: The nitro-vasodilators: New ideas about old drugs. Circulation 1993:87:1461-1467.
19. Macho P. Vatner SF: Effects of nitroglycerin and nitroprusside on large and small coronary vessels in conscious dogs. Circulation 1981: 64:1101-1107.
20. Jackson CV. Mickelson JK. Pope TK, Rao PS. Lucchesi BR: O2 free radical-mediated myocardial and vascular dysfunction. Am J Physiol 1986;251:H1225-H1231.
21. Stewart DJ. Pohl U, Bassenge E: Free radicals inhibit endothelium-dependent dilation in the coronary resistance bed. Am J Physiol 1988; 255:H765-H769.